Ikarian Capital’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-35,119
| Closed | -$707K | – | 172 |
|
|
2026
Q1 | $707K | Hold |
35,119
| – | – | 0.06% | 118 |
|
|
2025
Q4 | $567K | Buy |
+35,119
| New | +$465K | 0.04% | 135 |
|
|
2025
Q3 | – | Sell |
-198,528
| Closed | -$2.74M | – | 184 |
|
|
2025
Q2 | $2.24M | Buy |
+198,528
| New | +$2.43M | 0.43% | 63 |
|
|
2023
Q4 | – | Sell |
-142,692
| Closed | -$1.37M | – | 159 |
|
|
2023
Q3 | $1.37M | Buy |
142,692
+2,692
| +2% | +$27.5K | 0.17% | 91 |
|
|
2023
Q2 | $1.26M | Hold |
140,000
| – | – | 0.2% | 80 |
|
|
2023
Q1 | $1.1M | Buy |
+140,000
| New | +$1.04M | 0.25% | 73 |
|
|
2022
Q2 | – | Sell |
-39,730
| Closed | -$586K | – | 169 |
|
|
2022
Q1 | $586K | Buy |
39,730
+3,154
| +9% | +$45.3K | 0.08% | 124 |
|
|
2021
Q4 | $484K | Sell |
36,576
-60,000
| -62% | -$955K | 0.07% | 129 |
|
|
2021
Q3 | $1.69M | Sell |
96,576
-389
| -0.4% | -$7.88K | 0.12% | 133 |
|
|
2021
Q2 | $2.32M | Sell |
96,965
-200,000
| -67% | -$5.23M | 0.19% | 121 |
|
|
2021
Q1 | $7.63M | Sell |
296,965
-766,996
| -72% | -$20.2M | 0.26% | 86 |
|
|
2020
Q4 | $20.2M | Sell |
1,063,961
-171,510
| -14% | -$2.94M | 0.89% | 21 |
|
|
2020
Q3 | $15.6M | Buy |
1,235,471
+122,076
| +11% | +$1.53M | 1.13% | 21 |
|
|
2020
Q2 | $13.5M | Buy |
1,113,395
+166,790
| +18% | +$1.77M | 1.07% | 29 |
|
|
2020
Q1 | $7.24M | Buy |
946,605
+734,185
| +346% | +$9.91M | 0.54% | 49 |
|
|
2019
Q4 | $3.78M | Buy |
+212,420
| New | +$2.77M | 0.61% | 45 |
|
Other funds holding KALV
Ikarian Capital's KALV Position: Q2 2026 in Review
Ikarian Capital sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 35,119 shares — an estimated $707K sold.
Ikarian Capital first reported a position in KALV in Q4 2019 and held it in 16 quarters. The position peaked at $20.2M in Q4 2020. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Ikarian Capital reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Ikarian Capital sold 35,119 KalVista Pharmaceuticals shares in Q2 2026, an estimated $707K.
- Ikarian Capital first reported a position in KalVista Pharmaceuticals in Q4 2019 and held it in 16 quarters.
- Ikarian Capital's KalVista Pharmaceuticals position peaked at $20.2M in Q4 2020.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.